LONIDAMINE

Details

Stereochemistry	ACHIRAL
Molecular Formula	C15H10Cl2N2O2
Molecular Weight	321.158
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

OC(=O)C1=NN(CC2=CC=C(Cl)C=C2Cl)C3=C1C=CC=C3

InChI

InChIKey=WDRYRZXSPDWGEB-UHFFFAOYSA-N

InChI=1S/C15H10Cl2N2O2/c16-10-6-5-9(12(17)7-10)8-19-13-4-2-1-3-11(13)14(18-19)15(20)21/h1-7H,8H2,(H,20,21)

HIDE SMILES / InChI

Molecular Formula	C15H10Cl2N2O2
Molecular Weight	321.158
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/27497601
Curator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/12814259 | https://www.ncbi.nlm.nih.gov/pubmed/12972521 | https://www.ncbi.nlm.nih.gov/pubmed/7285632 | https://www.ncbi.nlm.nih.gov/pubmed/26831515

Lonidamine is a derivative of the indazole-3-carboxylic acid, with limited antineoplastic activity as a single agent but with exceptional potential in modulating the activities of conventional chemotherapeutic agents such as N-mustard alkylating agents and anthracyclines as well as hyperthermia, radiation therapy and photodynamic therapy. The most critical property of Lonidamine is its selective activity against a broad range of tumors with little to no effect on normal tissues provided that doses are below a threshold level of ~400 mg/m^2 (oral or i.v. doses). Selective effects of Lonidamine on tumors compared to other potential targets probably result from the dependence of most tumors on glycolytic metabolism, but the exact mechanism of specificity is still not fully known. Current evidence indicates that Lonidamine inhibits lactate export by the proton-linked monocarboxylate transporter(s) (MCT) and pyruvate uptake into mitochondria via the mitochondrial pyruvate carrier (MPC), whereas inhibition of respiration involves both diminished mitochondrial uptake of pyruvate via the MPC as well as inhibition of the mitochondrial electron-transport chain at Complex II and perhaps also Complex I, in both instances at the ubiquinone reduction step. There is also evidence that the drug may indirectly inhibit hexokinase as well as possibly other glycolytic and pentose shunt enzymes as a result of cytosolic acidification. Key problems that remain to be addressed are the production of Lonidamine under GMP conditions since Angelini Pharmaceuticals in Rome, Italy, the sole commercial source of this drug, stopped producing it in 2006. In addition, utilization of Lonidamine in the US requires IND approval by the FDA, which has previously been granted for a number of clinical trials. Finally, even though LND is a potent enhancer of the activity of a number of potent anti-cancer agents, potentially less toxic (and patentable) “targeted-tumor agents” are replacing traditional chemotherapy. Another problem remaining to be addressed is the limited solubility of Lonidamine at neutral pH. Oral delivery has led to variable results; more soluble derivatives that can be administered by the intravenous administration are needed to accurately control the dosing schedules.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Potency
Monocarboxylate transporter 1 2 Target ID: CHEMBL4360 Sources: https://www.ncbi.nlm.nih.gov/pubmed/27497601	Inhibitor 8504	36.8 µM [Kd]
Monocarboxylate transporter 2 6 Target ID: CHEMBL2073704 Sources: https://www.ncbi.nlm.nih.gov/pubmed/27497601	Inhibitor 8504	36.4 µM [Kd]
Monocarboxylate transporter 4 1 Target ID: CHEMBL2073663 Sources: https://www.ncbi.nlm.nih.gov/pubmed/27497601	Inhibitor 8504	40.4 µM [Kd]

Conditions

Condition	Modality	Highest Phase	Product
Prostatic hyperplasia 4 Sources: https://clinicaltrials.gov/ct2/show/NCT00237536	Primary	Phase II 1147	Unknown Approved Use Unknown
Breast cancer 432 Sources: https://www.ncbi.nlm.nih.gov/pubmed/12972521	Primary	Not Provided 511	Unknown Approved Use Unknown
Glioblastoma multiforme 30 Sources: https://www.ncbi.nlm.nih.gov/pubmed/12814259	Primary	Phase II 1147	Unknown Approved Use Unknown
Ovarian cancer 160 Sources: https://www.ncbi.nlm.nih.gov/pubmed/11239758	Primary	Phase II 1147	Unknown Approved Use Unknown

C_max

Value	Dose	Analyte	Population
15.5 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1911204/	150 mg single, oral dose: 150 mg route of administration: Oral experiment type: SINGLE co-administered:	LONIDAMINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE food status: UNKNOWN
22.4 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6717895/	600 mg single, oral dose: 600 mg route of administration: Oral experiment type: SINGLE co-administered:	LONIDAMINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
21.8 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6717895/	300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered:	LONIDAMINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED

AUC

Value	Dose	Co-administered	Analyte	Population
186.2 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6717895/	600 mg single, oral dose: 600 mg route of administration: Oral experiment type: SINGLE co-administered:		LONIDAMINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
136.1 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6717895/	300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered:		LONIDAMINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED

T_1/2

Value	Dose	Analyte	Population
3.9 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1911204/	150 mg single, oral dose: 150 mg route of administration: Oral experiment type: SINGLE co-administered:	LONIDAMINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE food status: UNKNOWN
12.1 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6717895/	600 mg single, oral dose: 600 mg route of administration: Oral experiment type: SINGLE co-administered:	LONIDAMINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
14.8 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6717895/	300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered:	LONIDAMINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED

Doses

Dose	Population	Adverse events
520 mg/m2 3 times / day multiple, oral Highest studied dose Dose: 520 mg/m2, 3 times / day Route: oral Route: multiple Dose: 520 mg/m2, 3 times / day Sources: https://www.karger.com/Article/Abstract/225888	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://www.karger.com/Article/Abstract/225888	DLT: Myalgia... Other AEs: Testicula pain, Chest pain... Dose limiting toxicities: Myalgia (grade 1-3, 100%) Other AEs: Testicula pain (grade 1-4, 33.3%) Chest pain (grade 2-3, 33.3%) Photophobia (grade 4, 16.7%) Ototoxicity (grade 1, 16.7%) Nausea (grade 1-2, 33.3%) Sources: https://www.karger.com/Article/Abstract/225888

AEs

AE	Significance	Dose	Population
Ototoxicity	grade 1, 16.7%	520 mg/m2 3 times / day multiple, oral Highest studied dose Dose: 520 mg/m2, 3 times / day Route: oral Route: multiple Dose: 520 mg/m2, 3 times / day Sources: https://www.karger.com/Article/Abstract/225888	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://www.karger.com/Article/Abstract/225888
Nausea	grade 1-2, 33.3%	520 mg/m2 3 times / day multiple, oral Highest studied dose Dose: 520 mg/m2, 3 times / day Route: oral Route: multiple Dose: 520 mg/m2, 3 times / day Sources: https://www.karger.com/Article/Abstract/225888	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://www.karger.com/Article/Abstract/225888
Myalgia	grade 1-3, 100% DLT	520 mg/m2 3 times / day multiple, oral Highest studied dose Dose: 520 mg/m2, 3 times / day Route: oral Route: multiple Dose: 520 mg/m2, 3 times / day Sources: https://www.karger.com/Article/Abstract/225888	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://www.karger.com/Article/Abstract/225888
Testicula pain	grade 1-4, 33.3%	520 mg/m2 3 times / day multiple, oral Highest studied dose Dose: 520 mg/m2, 3 times / day Route: oral Route: multiple Dose: 520 mg/m2, 3 times / day Sources: https://www.karger.com/Article/Abstract/225888	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://www.karger.com/Article/Abstract/225888
Chest pain	grade 2-3, 33.3%	520 mg/m2 3 times / day multiple, oral Highest studied dose Dose: 520 mg/m2, 3 times / day Route: oral Route: multiple Dose: 520 mg/m2, 3 times / day Sources: https://www.karger.com/Article/Abstract/225888	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://www.karger.com/Article/Abstract/225888
Photophobia	grade 4, 16.7%	520 mg/m2 3 times / day multiple, oral Highest studied dose Dose: 520 mg/m2, 3 times / day Route: oral Route: multiple Dose: 520 mg/m2, 3 times / day Sources: https://www.karger.com/Article/Abstract/225888	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://www.karger.com/Article/Abstract/225888

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
inhibitor 2252	inhibitor 2438	inhibitor 2507	inhibitor 2217

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
BCRP 910 OATP1B1 1079 CYP2C19 2057 CYP1A2 2153 OATP1B3 961 P-gp 1741	P-gp 2052

Drug as perpetrator

Target	Modality	Activity
CYP3A4 2633	inhibitor 4027 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwzNDAiLCJ1c2VfY3VzdG9tX3F1ZXJ5Ijp0cnVlLCJzZWFyY2hfdGVybSI6IiIsInRleHRfZmlsdGVyIjoiQ0hFTUJMMTI1NzAzMCJ9fQ==	inconclusive [IC50 2.5119 uM]
CYP2C9 2497	inhibitor 4027 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwzMzk3IiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDEyNTcwMzAifX0=	inconclusive [IC50 31.8107 uM]
CYP1A2 2333	inhibitor 4027 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwzMzU2IiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDEyNTcwMzAifX0=	inconclusive [IC50 39.8107 uM]
CYP2D6 2546	inhibitor 4027 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwyODkiLCJ1c2VfY3VzdG9tX3F1ZXJ5Ijp0cnVlLCJzZWFyY2hfdGVybSI6IiIsInRleHRfZmlsdGVyIjoiQ0hFTUJMMTI1NzAzMCJ9fQ==	no [IC50 31.6628 uM]
CYP2C19 2141	inhibitor 4027 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwzNjIyIiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDEyNTcwMzAifX0=	no [IC50 >10 uM]
BCRP 985	inhibitor 4027 Sources: https://pubchem.ncbi.nlm.nih.gov/compound/39562#section=BioAssay-Results Page: 74.0	no
P-gp 1932	inhibitor 4027 Sources: https://pubchem.ncbi.nlm.nih.gov/compound/39562#section=BioAssay-Results Page: 76.0	no
OATP1B1 1095	inhibitor 4027 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwxNjk3NjY4IiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDEyNTcwMzAifX0=	yes [Inhibition 10 uM]
OATP1B3 970	inhibitor 4027 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwxNzQzMTIxIiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDEyNTcwMzAifX0=	yes [Inhibition 10 uM]

Drug as victim

Target	Modality	Activity	Metabolite	Clinical evidence
P-gp 2052	substrate 4014 Sources: https://pubchem.ncbi.nlm.nih.gov/compound/39562#section=BioAssay-Results Page: 278.0	no

Tox targets

Target	Modality	Activity	Metabolite	Clinical evidence
hERG 2263	inhibitor 2237 Sources: https://pubchem.ncbi.nlm.nih.gov/compound/39562#section=BioAssay-Results Page: 235.0

PubMed

Title	Date	PubMed
New scaffolds of natural origin as Integrase-LEDGF/p75 interaction inhibitors: virtual screening and activity assays.	2013-10	23994868
2-Deoxy-D-glucose cooperates with arsenic trioxide to induce apoptosis in leukemia cells: involvement of IGF-1R-regulated Akt/mTOR, MEK/ERK and LKB-1/AMPK signaling pathways.	2012-12-15	23041229
Increased apoptotic efficacy of lonidamine plus arsenic trioxide combination in human leukemia cells. Reactive oxygen species generation and defensive protein kinase (MEK/ERK, Akt/mTOR) modulation.	2011-12-01	21889928
Discovery of N-hydroxyindole-based inhibitors of human lactate dehydrogenase isoform A (LDH-A) as starvation agents against cancer cells.	2011-03-24	21332213
Adjudin-mediated Sertoli-germ cell junction disassembly affects Sertoli cell barrier function in vitro and in vivo.	2010-11	20713173
Curcumin stimulates reactive oxygen species production and potentiates apoptosis induction by the antitumor drugs arsenic trioxide and lonidamine in human myeloid leukemia cell lines.	2010-10	20605902
AF-2364 is a prospective spermicide candidate.	2010-05	20418891
The fourth isoform of the adenine nucleotide translocator inhibits mitochondrial apoptosis in cancer cells.	2010-05	20060930
A target-based high throughput screen yields Trypanosoma brucei hexokinase small molecule inhibitors with antiparasitic activity.	2010-04-13	20405000
Cancer as a metabolic disease.	2010-01-27	20181022
Improving outcome of chemotherapy of metastatic breast cancer by docosahexaenoic acid: a phase II trial.	2009-12-15	19920822
International guidelines for management of metastatic breast cancer: combination vs sequential single-agent chemotherapy.	2009-09-02	19657108
Modulation of cellular radiation responses by 2-deoxy-D-glucose and other glycolytic inhibitors: implications for cancer therapy.	2009-09	20009297
Development of a yeast bio-assay to screen anti-mitochondrial drugs.	2009-09	19496752
Human cytomegalovirus US9 protein contains an N-terminal signal sequence and a C-terminal mitochondrial localization domain, and does not alter cellular sensitivity to apoptosis.	2009-05	19264602
Effects of fotemustine or dacarbasine on a melanoma cell line pretreated with therapeutic proton irradiation.	2009-04-09	19358719
Inhibition of glycolysis modulates prednisolone resistance in acute lymphoblastic leukemia cells.	2009-02-26	18978206
Drugs targeting the mitochondrial pore act as cytotoxic and cytostatic agents in temozolomide-resistant glioma cells.	2009-02-05	19196452
Whole brain radiotherapy with radiosensitizer for brain metastases.	2009-01-06	19126230
Quality of life in brain metastases radiation trials: a literature review.	2008-10	19008990
Neuropsychological testing and biomarkers in the management of brain metastases.	2008-09-17	18798997
Optimizing radiotherapy of brain tumours by a combination of temozolomide & lonidamine.	2008-08	19001677
Glycosyl and polyalcoholic prodrugs of lonidamine.	2008-04-01	18321702
The anti-trypanosomal agent lonidamine inhibits Trypanosoma brucei hexokinase 1.	2008-04	18262292
Canadian supportive care recommendations for the management of neutropenia in patients with cancer.	2008-01	18317581
Arsenic-based antineoplastic drugs and their mechanisms of action.	2008	18431449
[Treatment and post-treatment with lonidamine in human colon carcinoma HT-29 cell line].	2008	18416315
The oncoprotein H-RasV12 increases mitochondrial metabolism.	2007-12-01	18053146
CFTR-dependent Cl- secretion in Xenopus laevis lung epithelium.	2007-08-15	17490919
Immunohistochemical profile of some neurotransmitters and neurotrophins in the seminiferous tubules of rats treated by lonidamine.	2007-06-06	17548265
Evaluation of contraceptive activity of methanol extract of Dendrophthoe falcata stem in male albino rats.	2007-05-30	17446020
Lonidamine affects testicular steroid hormones in immature mice.	2007-05-15	17442358
Mitomycin C and Vinorelbine for second-line chemotherapy in NSCLC--a phase II trial.	2007-04-10	17353918
The H+-linked monocarboxylate transporter (MCT1/SLC16A1): a potential therapeutic target for high-risk neuroblastoma.	2006-12	17000864
Pharmacologic inhibitors of extracellular signal-regulated kinase (ERKs) and c-Jun NH(2)-terminal kinase (JNK) decrease glutathione content and sensitize human promonocytic leukemia cells to arsenic trioxide-induced apoptosis.	2006-12	16972261
Ten years of experience with weekly chemotherapy in metastatic breast cancer patients: multivariate analysis of prognostic factors.	2006-11	17075319
Chemosensitization by knockdown of adenine nucleotide translocase-2.	2006-09-15	16982757
Does granulocyte colony-stimulating factor worsen anemia in early breast cancer patients treated with epirubicin and cyclophosphamide?	2006-07-01	16769988
Emerging drug therapies for benign prostatic hyperplasia.	2006-03	16503830
Administration of zoledronic acid enhances the effects of docetaxel on growth of prostate cancer in the bone environment.	2006-01-17	16417633
[Antimitochondrial agents: a new class of anticancer agents].	2006-01	16298120
Surrogate markers and survival in women receiving first-line combination anthracycline chemotherapy for advanced breast cancer.	2005-11-28	16278665
Impact of five prophylactic filgrastim schedules on hematologic toxicity in early breast cancer patients treated with epirubicin and cyclophosphamide.	2005-10-01	16129844
Long-term effects of lonidamine on mouse testes.	2005-10	16181970
Lonidamine transiently affects spermatogenesis in pubertal CD1 mice.	2005-10	16181969
Contribution of gap junctional communication between tumor cells and astroglia to the invasion of the brain parenchyma by human glioblastomas.	2005-02-16	15715906
Mitomycin C, vinblastine and cisplatin (MVP): an active and well-tolerated salvage regimen for advanced breast cancer.	2005-02-14	15685237
Clinical Evidence Supporting the Role of Lonidamine for the Treatment of BPH.	2005	16986058
Lonidamine: basic science and rationale for treatment of prostatic proliferative disorders.	2005	16986057
The development of lonidamine for benign prostatic hyperplasia and other indications.	2005	16986056

Patents

Sample Use Guides

In Vivo Use Guide

450 mg/day

Route of Administration: Oral

In Vitro Use Guide

A malignant human glioma (U373MG) cell line was used in these studies. TMZ (temozolomide) (20, 40 or 60 microM) or LND (Lonidamine) (100, 150 or 200 microM), or the combination of both (20 and 100 microM, respectively) in 0.1 per cent dimethyl sulphoxide (DMSO) were added three days after setting up cultures, in six well plates (5 x 10(4) cells/ well). The effects of continuous treatment for two days on proliferation response and cytotoxicity were studied after trypsinization; by cell counts and the uptake of trypan blue dye (0.5%). For the study of radiation (60Co-Gamma-rays, 2 Gy) response, drugs were removed 4 h after irradiation and cultures were grown further in drug free, normal growth medium for another 20 h or 44 h.

Substance Class	Chemical Created by `admin` on `Wed Apr 02 07:37:07 GMT 2025` Edited by `admin` on `Wed Apr 02 07:37:07 GMT 2025`
Record UNII	U78804BIDR
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

DORIDAMINA

Preferred Name

English

LONIDAMINE

Official Name

English

LONIDAMINE [MART.]

Common Name

English

LONIDAMINE [MI]

Common Name

English

NSC-758419

Code

English

lonidamine [INN]

Common Name

English

Lonidamine [WHO-DD]

Common Name

English

NSC-741419

Code

English

1-(2,4-DICHLOROBENZYL)-1H-INDAZOLE-3-CARBOXYLIC ACID

Systematic Name

English

1-(2,4-DICHLOROPHENYL)-1H-INDAZOL-3-CARBOXYLIC ACID

Systematic Name

English

Classification Tree Code System Code

NCI_THESAURUS

C798